Development and Validation of Interpretable Machine Learning Models Incorporating Paraspinal Muscle Quality for to Predict Cage Subsidence Risk Followingposterior Lumbar Interbody Fusion
Launched by HAO LIU · Mar 17, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. confirmed lumbar disc herniation, spinal stenosis, or spondylolisthesis based on clinical and imaging findings;
- • 2. patients who failed conservative treatment for ≥3 months or experienced recurrence and underwent surgery for the first time;
- • 3. minimum 12-month follow-up.
- Exclusion Criteria:
- • 1. prior spinal surgery;
- • 2. spinal deformity or severe instability;
- • 3. lumbar tuberculosis, infection, tumor, or severe bone destruction;
- • 4. incomplete or lost follow-up.
About Hao Liu
Hao Liu is a dedicated clinical trial sponsor with a strong focus on advancing medical research and improving patient outcomes. With extensive experience in managing and overseeing clinical studies, Hao Liu is committed to ensuring the integrity, safety, and efficacy of innovative therapies. The organization emphasizes collaboration with healthcare professionals and regulatory bodies to facilitate the development of groundbreaking treatments. By leveraging cutting-edge methodologies and adhering to stringent ethical standards, Hao Liu aims to contribute significantly to the advancement of medical science and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jiangsu, Suzhou, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported